Diabetes

Tracey D. Brown will welcome 16,000 attendees to the premier diabetes health care conference in her first month as chief executive of the American Diabetes Association.

The American Diabetes Association at its 78th Scientific Sessions will recognize 4 physicians who have worked to advance diabetes research and improve patient health outcomes.

At the American Pharmacy Purchasing Alliance's PharmCon, Michael Castagna, PharmD, MBA, and CEO of Mannkind Corporation discussed the need for a larger focus on patient outcomes in order to better address the diabetes pandemic occurring in the United States.

The Working Group examined the insulin supply chain and the factors that impact the costs of and access to insulin products.

At the American Pharmacy Purchasing Alliance’s PharmCon in Orlando, FL, experts with collaborative practice experience discussed why these pharmacist-physician partnerships are useful, and how they can effectively work.

Some 13,000 health care professionals from around the world convene each year at this popular meeting to discuss case studies, sympsia, oral presentations, and other forms of new research.

Half of people who have diabetes eventually develop diabetic peripheral neuropathy, and the warning signs are sensory symptoms that start in the distant periphery and progressing in a characteristic 'glove and stocking' way.

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

An evaluation of the impact of persistence to oral antidiabetic medication on reducing the risk of hospitalization in adult patients with type 2 diabetes.

Kidney disease occurs along a continuum, and for people who have diabetes, the risk of developing kidney disease is significantly elevated.

For health care providers, staying up to date on drug development trends is crucial to understanding the implications of these therapies and how they can best help their patients.

LifePlus has announced their product Lifeleaf, which is an noninvasive monitor for glucose, blood pressure, heart rate, respiration rate, and oxygen saturation. How can change the field of wearables?

Sanofi announced that the FDA has accepted the New Drug Application (NDA) for Zynquista (sotagliflozin).

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Population-based screening was found to be associated with a reduction in admissions, physician visits, and prescribed medication for individuals diagnosed with type 2 diabetes.

CVS Health's Chief Medical Officer Troyen A. Brennan, MD, outlined how the combination of data-driven insights, and the convenience of community-based retail health care can provide a highly personalized health care experience that supports the primary care medical home, and can improve patient outcomes and lower costs.

Patients with diabetes taking canagliflozin achieved better glycemic control, were less likely to stop taking the medication, and were less likely to switch to another drug.

Upgrades to the insulin pen to improve disease management and prevent hypoglycemia due to overdoses are on the horizon.

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

One Drop is a company that has a great holistic service using CDE to help patients get their diabetes better controlled, and recent data support their mission.

The health insurer recently launched its Emerging Solutions' platform.

Certified Diabetes Educators (CDEs) can make a tremendous difference in the lives of people who have diabetes.

An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study.

Researchers concluded that metformin may reduce risk of nonsevere statin muscle pain.